Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Diabetes mellitus is the leading cause of end-stage renal disease (ESRD) worldwide.
Read More »Renal Outcomes After Canagliflozin Use in Patients with Type 2 Diabetes
CV Benefit of GLP-1 Agonists and SGLT2 Inhibitors Misleading for Black Patients? ADA
Claims of improved cardiovascular outcomes from GLP-1 agonists and SGLT2 inhibitors not proven significant for black patients.
Read More »Caution for Using SGLT-2 Inhibitors in Type 1 Diabetes: ADA
There is currently a huge unmet need for non-insulin add on therapy in type 1 diabetes, but are SGLT inhibitors the right drug for the job?
Read More »EMPA-REG OUTCOME Trial: Reducing Cardiovascular Risk For T2D Patients
The results of EMPA-REG OUTCOME Trial assess the role of empagliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Read More »CREDENCE Trial Shows Renal and Cardiovascular Protection
Strong results motivate the ADA to update its Standard of Care for patients with diabetes.
Read More »Beware: Diuretics Can Increase Risk of Amputations
Adding a SGLT-2 inhibitor which acts as a diuretic can increase the risk.
Read More »Canagliflozin Study Stopped Early Due to Positive Results in Reducing CKD, Death and ESRD
Featuring exclusive comments from Dr. George Bakris
Studies are rarely stopped early; when it happens, we should take notice of the results.
GLP-1RA as Add-on Therapy to SGLT-2 Inhibitor
Combination treatment can help improve glucose levels in patients with elevated HbA1Cs.
Read More »Sedentary Behavior During Pregnancy and Neonatal Adiposity
Lifestyle intervention in pregnancy might reduce adverse effects of maternal obesity on neonatal adiposity.
Read More »First Dual SGLT-1/2 Inhibitor For Adults With Type 1 Declined Approval
Sanofi and Lexicon to continue any required studies in effort to move sotagliflozin forward.
Read More »